Abstract
In Alzheimerss disease (AD) a disturbed balance between synthesis and removal of Aβ leads to the formation of Aβ deposits and a reaction of the innate immune system. Little evidence exists for a contribution of the adaptive immune response in AD, as no signs of influx of blood borne cells or presence of immunoglobulins in Aβ deposits are apparent. Factors of the complement (C) system and pentraxins act as pattern recognition molecules and mediate uptake of Aβ by glial cells expressing C-receptors (Crec). These interactions may, however, also lead to synthesis and secretion of reactive oxygen species (ROS), cytokines, chemokines and other potentially neurotoxic agents by the glial cells. Virtually all complement factors are produced in brain, and the expression is increased in AD affected brain areas. In AD brain areas with amyloid deposits especially classical pathway C activation products are readily observed. Also C regulatory proteins (Creg) and Crec can be found in the brain parenchyma and are upregulated, especially under acute inflammatory conditions, such as meningitis. However, under chronic low-grade inflammatory conditions, such as in AD, Creg and to some extent Crec expression may remain at a low level, thereby allowing C activation to proceed, leading to sustained activation of glial cells and neurodegenerative changes. In this review evidence from immunohistochemical, in vitro and animal studies pointing to a role for C activation is discussed, with special focus on the disturbed balance between C activators and Cregs in AD.
Keywords: Complement, complement receptors, Alzheimer's disease, amyloid, microglia, neuroinflammation, Amyloid plaques, Vascular amyloid, Cerebral amyloid angiopathy, Age related macula degeneration (AMD), Complement regulatory proteins (Creg), C1q, C1-Inhibitor, Factor H, Clusterin
Current Alzheimer Research
Title: Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Volume: 8 Issue: 1
Author(s): Robert Veerhuis
Affiliation:
Keywords: Complement, complement receptors, Alzheimer's disease, amyloid, microglia, neuroinflammation, Amyloid plaques, Vascular amyloid, Cerebral amyloid angiopathy, Age related macula degeneration (AMD), Complement regulatory proteins (Creg), C1q, C1-Inhibitor, Factor H, Clusterin
Abstract: In Alzheimerss disease (AD) a disturbed balance between synthesis and removal of Aβ leads to the formation of Aβ deposits and a reaction of the innate immune system. Little evidence exists for a contribution of the adaptive immune response in AD, as no signs of influx of blood borne cells or presence of immunoglobulins in Aβ deposits are apparent. Factors of the complement (C) system and pentraxins act as pattern recognition molecules and mediate uptake of Aβ by glial cells expressing C-receptors (Crec). These interactions may, however, also lead to synthesis and secretion of reactive oxygen species (ROS), cytokines, chemokines and other potentially neurotoxic agents by the glial cells. Virtually all complement factors are produced in brain, and the expression is increased in AD affected brain areas. In AD brain areas with amyloid deposits especially classical pathway C activation products are readily observed. Also C regulatory proteins (Creg) and Crec can be found in the brain parenchyma and are upregulated, especially under acute inflammatory conditions, such as meningitis. However, under chronic low-grade inflammatory conditions, such as in AD, Creg and to some extent Crec expression may remain at a low level, thereby allowing C activation to proceed, leading to sustained activation of glial cells and neurodegenerative changes. In this review evidence from immunohistochemical, in vitro and animal studies pointing to a role for C activation is discussed, with special focus on the disturbed balance between C activators and Cregs in AD.
Export Options
About this article
Cite this article as:
Veerhuis Robert, Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD, Current Alzheimer Research 2011; 8 (1) . https://dx.doi.org/10.2174/156720511794604589
DOI https://dx.doi.org/10.2174/156720511794604589 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Newer Avenues for the Treatment of Leptomeningeal Carcinomatosis
Central Nervous System Agents in Medicinal Chemistry The Tortuous Road to an Ideal CGRP Function Blocker for the Treatment of Migraine
Current Topics in Medicinal Chemistry Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Delirium in Older Patients – A Review
Current Psychiatry Reviews Coagulation and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia
Current Cancer Drug Targets Mass Spectrometry, Proteomics, Data Mining Strategies and Their Applications in Infectious Disease Research.
Anti-Infective Agents in Medicinal Chemistry Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain
Current Drug Targets Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis
Current Drug Discovery Technologies Preface
Current Drug Targets - Infectious Disorders Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets Hybrid Drugs as Potential Combatants Against Drug-Resistant Microbes: A Review
Current Topics in Medicinal Chemistry Physiological Roles of Neurite Outgrowth Inhibitors in Myelinated Axons of the Central Nervous System – Implications for the Therapeutic Neutralization of Neurite Outgrowth Inhibitors
Current Pharmaceutical Design Recent Advances on Neural Tube Defects with Special Reference to Valproic Acid
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery The Multi-faceted Profile of Corticotropin-releasing Factor (CRF) Family of Neuropeptides and of their Receptors on the Paracrine/Local Regulation of the Inflammatory Response
Current Molecular Pharmacology Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Current Drug Targets Atypical Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children: A Systematic Review
Current Pediatric Reviews